Kentucky reaches OxyContin, Risperdal settlements; Valeant's Walgreens pact won't solve its growth problems;

> Kentucky has reached two separate settlements totaling $39.5 million--one each with Purdue and Johnson & Johnson ($JNJ) over their respective meds, OxyContin and Risperdal. More

> Valeant's ($VRX) new pricing and distribution pact with Walgreens ($WBA) likely won't bring the company the same revenue growth it generated with high-priced branded drugs, doctors and investors say. More

> India has added drugs for cancer, HIV/AIDS and hepatitis C to its essential medicines list in hopes of making them more affordable. More

> The New England Journal of Medicine has published positive results of two trials of Novartis' ($NVS) Cosentyx in ankylosing spondylitis. Release

And Finally... The U.S. Drug Enforcement Agency (DEA) is easing the regulatory requirements that were previously imposed on those conducting FDA-approved clinical trials on cannabidiol. More

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.